Jeffrey Hamby, MD
Family Medicine · van Buren, ARNPI 1831178524
Payments from drug & device makers
Across 361 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$599
- AstraZeneca$508
- Sunovion Pharmaceuticals Inc.$507
- Amgen$208
- Lilly USA, LLC$198
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$3,50042%
- Food & beverage$4,76257%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $4,824 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $599 |
| AstraZeneca | 10 | $508 |
| Sunovion Pharmaceuticals Inc. | 47 | $507 |
| Amgen(2 entities) | 13 | $208 |
| Lilly USA, LLC | 14 | $198 |
| Novo Nordisk | 12 | $162 |
| Bayer | 9 | $132 |
| GSK | 9 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $130 |
| Pfizer | 7 | $102 |
| Otsuka America Pharmaceutical, Inc. | 6 | $85 |
| Johnson & Johnson | 7 | $84 |
| Corium, LLC | 3 | $63 |
| Shire North American Group Inc | 4 | $48 |
| Sanofi-aventis U.S. LLC | 4 | $48 |
| Antares Pharma, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Abbott | 2 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Axsome Therapeutics, Inc. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Harmony Biosciences LLC | 1 | $19 |
| Gilead | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| Alkermes, Inc. | 1 | $12 |
| Bioventus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,303 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $221,799 |
| FarxigaDapagliflozin Propanediol | 131 | $145,685 |
| EliquisApixaban | 138 | $126,217 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $72,033 |
| MounjaroTirzepatide | 25 | $44,248 |
| XareltoRivaroxaban | 41 | $39,001 |
| JardianceEmpagliflozin | 29 | $38,905 |
| TrulicityDulaglutide | 23 | $38,519 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $37,979 |
| Nurtec OdtRimegepant Sulfate | 14 | $27,903 |
| LinzessLinaclotide | 24 | $23,143 |
| MovantikNaloxegol Oxalate | 30 | $22,127 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $21,608 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 711 | $18,943 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $18,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $162 | $221,799169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $508 | $191,456174 claims |
| PfizerEliquis, Nurtec Odt | $102 | $154,120152 claims |
| Lilly USA, LLCMounjaro, Trulicity | $198 | $82,76748 claims |
| GSKTrelegy Ellipta | $131 | $72,03357 claims |
| Johnson & JohnsonXarelto | $84 | $39,00141 claims |
| Boehringer IngelheimJardiance | $28 | $38,90529 claims |
| AbbVieLinzess, Synthroid | $4,824 | $26,00765 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Uloric | $130 | $3,72612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in van Buren
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.